A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer

A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer

Meng Zhou,1,* Xiaoyu Wang,1,* Jie Xia,2 Yating Cheng,1 Lichun Xiao,1 Yu Bei,3 Jianzhong Tang,3 Yadong Huang,1,3 Qi Xiang,1,3 Shiliang Huang2 1Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University, Guangzhou 510632, People’s Republic o...

Full description

Bibliographic Details
Main Authors:	Zhou M, Wang X, Xia J, Cheng Y, Xiao L, Bei Y, Tang J, Huang Y, Xiang Q, Huang S
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-05-01
Series:	International Journal of Nanomedicine
Subjects:	mansonone derivative conjugate of her2 monoclonal antibody extracellular fragment 4d5 castration-resistant prostate cancer
Online Access:	https://www.dovepress.com/a-mansonone-derivative-coupled-with-monoclonal-antibody-4d5-modified-c-peer-reviewed-article-IJN

Similar Items

Antimicrobial, herbicidal and antifeedant activities of mansonone E from the heartwoods of Mansonia gagei Drumm.
by: Rachsawan Mongkol, et al.
Published: (2016-12-01)

Enhanced Solubility and Anticancer Potential of Mansonone G By β-Cyclodextrin-Based Host-Guest Complexation: A Computational and Experimental Study
by: Panupong Mahalapbutr, et al.
Published: (2019-09-01)

Experimental study of apoptosis in the prostate tissue following castration
by: Y Doustar, et al.
Published: (2008-02-01)

Butoxy Mansonone G Inhibits STAT3 and Akt Signaling Pathways in Non-Small Cell Lung Cancers: Combined Experimental and Theoretical Investigations
by: Panupong Mahalapbutr, et al.
Published: (2019-03-01)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
by: Magdalena Schrank, et al.
Published: (2020-01-01)

Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer
by: Pascoe Abigail C, et al.
Published: (2012-03-01)

A Chemical Overview of Azanza garckeana
by: Yilni Edward Bioltif, et al.
Published: (2020-11-01)

Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer
by: Xiaocong Pang, et al.
Published: (2019-09-01)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
by: Lixin Mai, et al.
Published: (2020-12-01)

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
by: Caffo O, et al.
Published: (2016-12-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)
by: Zhu Y, et al.
Published: (2020-03-01)

Darolutamide For Castration-Resistant Prostate Cancer
by: Bastos DA, et al.
Published: (2019-10-01)

Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer
by: Kai-Fu Yang, et al.
Published: (2015-12-01)

EXPERIENCE WITH OCTREOTIDE IN PATIENTS WITH CASTRATION REFRACTORY PROSTATE CANCER
by: D. I. Ganov, et al.
Published: (2014-07-01)

EXPERIENCE WITH OCTREOTIDE IN PATIENTS WITH CASTRATION REFRACTORY PROSTATE CANCER
by: D. I. Ganov, et al.
Published: (2014-07-01)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
by: David Ka-Wai Leung, et al.
Published: (2021-03-01)

Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01)

Drug treatment opportunities of the elderly patients with the metastatic castration-resistant prostate cancer
by: V. A. Solodkiy, et al.
Published: (2017-04-01)

ROLE OF DEGARELIX (FIRMAGON) IN THE TREATMENT OF DISSEMINATED PROSTATE CANCER: CAN THE QUALITY OF CASTRATION THERAPY BE IMPROVED?
by: V. B. Matveev, et al.
Published: (2014-07-01)

ROLE OF DEGARELIX (FIRMAGON) IN THE TREATMENT OF DISSEMINATED PROSTATE CANCER: CAN THE QUALITY OF CASTRATION THERAPY BE IMPROVED?
by: V. B. Matveev, et al.
Published: (2014-07-01)

Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
by: Sanjoy Kumar Sureka, et al.
Published: (2016-01-01)

Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer
by: Anna S. Gerdtsson, et al.
Published: (2021-03-01)

Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice
by: Geehyun Song, et al.
Published: (2013-09-01)

Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy
by: Minyong Kang, et al.
Published: (2015-12-01)

Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
by: Ya V Gridneva, et al.
Published: (2014-09-01)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
by: Mark N Stein, et al.
Published: (2014-06-01)

AKR1C3 inhibition therapy in Castration-Resistant Prostate Cancer and Breast Cancer: Lessons from Responses to SN33638
by: Wen eZhou, et al.
Published: (2014-06-01)

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
by: Patel SA, et al.
Published: (2017-08-01)

Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in men with metastatic castration-resistant prostate cancer
by: Scott T Tagawa, et al.
Published: (2013-08-01)

Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer
by: Yi-Ping Zhu, et al.
Published: (2014-02-01)

The activity of SN33638, an inhibitor of AKR1C3, on testosterone and 17β-estradiol production and function in castration-resistant prostate cancer and ER-positive breast cancer
by: Yarong Diana eYin, et al.
Published: (2014-06-01)

Retreatment with cabazitaxel in a long-surviving patient with castration-resistant prostate cancer and visceral metastasis
by: Raquel Luque Caro, et al.
Published: (2018-01-01)

CURRENT POSSIBILITIES OF DRUG THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER
by: A. S. Markova
Published: (2014-07-01)

A changing landscape in castration resistant prostate cancer treatment
by: Alessandra eFelici, et al.
Published: (2012-07-01)

CURRENT POSSIBILITIES OF DRUG THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER
by: A. S. Markova
Published: (2014-07-01)

Prolactin promotes a partial recovery from the atrophy of both male and female gerbil prostates caused by castration
by: Marianna Zanatelli, et al.
Published: (2021-06-01)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
by: Atsushi Mizokami, et al.
Published: (2017-01-01)

Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer
by: Takeuchi T, et al.
Published: (2016-01-01)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
by: Monica Vidal, et al.